LongBio Pharma Lists on Hong Kong Stock Exchange
LongBio Pharma, an innovative drug developer for allergic and autoimmune diseases based in China, listed on the Hong Kong Stock Exchange on June 5, 2026. The company opened at HK$144.30 per share with a market capitalization of HK$10.7 billion after issuing shares at HK$96.06 each.
Topics: biotech IPO pharmaceuticals venture capital